[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Is Bristol-Myers Squibb Stock Underperforming the Dow?

Valued at a market cap of $112.2 billion, Bristol-Myers Squibb Company (BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products. The Princeton, New Jersey-based company offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas.

Companies worth $10 billion or more are typically classified as “large-cap stocks,” and BMY fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the drug manufacturers - general industry. The company's core specialty lies in its pioneering leadership across high-barrier therapeutic areas, specifically oncology, hematology, cardiovascular disease, and immunology, while aggressively expanding into next-generation...

Fundamentals

See More
  • Market Capitalization, $K 112,211,808
  • Shares Outstanding, K 2,042,071
  • Annual Sales, $ 48,194 M
  • Annual Income, $ 7,054 M
  • EBIT $ 12,521 M
  • EBITDA $ 16,532 M
  • 60-Month Beta 0.24
  • Price/Sales 2.42
  • Price/Cash Flow 7.03
  • Price/Book 5.81

Options Overview Details

View History
  • Implied Volatility 29.05% (+1.32%)
  • Historical Volatility 26.46%
  • IV Percentile 41%
  • IV Rank 41.90%
  • IV High 40.88% on 11/19/25
  • IV Low 20.52% on 12/31/25
  • Expected Move (DTE 3) 1.11 (2.03%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 55,479
  • Volume Avg (30-Day) 24,874
  • Put/Call OI Ratio 0.93
  • Today's Open Interest 658,946
  • Open Int (30-Day) 609,653
  • Expected Range 53.36 to 55.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.62
  • Number of Estimates 11
  • High Estimate $1.71
  • Low Estimate $1.53
  • Prior Year $1.46
  • Growth Rate Est. (year over year) +10.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
54.20 +0.48%
on 06/02/26
60.25 -9.61%
on 05/22/26
-3.76 (-6.46%)
since 05/01/26
3-Month
54.20 +0.48%
on 06/02/26
62.58 -12.98%
on 03/04/26
-7.88 (-12.64%)
since 03/02/26
52-Week
42.52 +28.08%
on 10/29/25
62.89 -13.40%
on 03/02/26
+5.67 (+11.62%)
since 06/02/25

Most Recent Stories

More News
Is Bristol-Myers Squibb Stock Underperforming the Dow?

Bristol-Myers Squibb has underperformed the Dow recently, yet analysts remain moderately optimistic about the stock’s prospects.

LLY : 1,064.15 (-1.67%)
$DOWI : 51,307.79 (+0.45%)
BMY : 54.46 (-0.89%)
Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

Interim analyses from PANKU-Breast02 (BL-B01D1-307) and PANKU-Esophagus01 (BL-B01D1-305) presented at ASCO ® 2026 ...

BMY : 54.46 (-0.89%)
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Camzyos has the potential to be the first pharmacological therapy for the treatment of oHCM in adolescents, addressing a high unmet need for this population ...

BMY : 54.46 (-0.89%)
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma

First-ever immunotherapy combination approved in Europe for adult and adolescent patients, ages 12 and older, with previously untreated Stage III or IV classical Hodgkin Lymphoma (cHL)

BMY : 54.46 (-0.89%)
Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q1

Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q1

BMY : 54.46 (-0.89%)
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma

First Phase 3 results for a CELMoD presented as late-breaking presentation at ASCO ® 2026 SUCCESSOR-2 data reinforce...

BMY : 54.46 (-0.89%)
Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Goldman Sachs 47 th Annual Global Healthcare Conference on Tuesday, June 9, 2026. ...

BMY : 54.46 (-0.89%)
1 Surging Stock with Promising Prospects and 2 We Ignore

1 Surging Stock with Promising Prospects and 2 We Ignore

KO : 78.41 (-0.29%)
VSH : 62.49 (+11.61%)
BMY : 54.46 (-0.89%)
Bristol-Myers Squibb Stock Rises on Anthropic AI Deal. Why This Could Actually Be a Key Upside Catalyst.

BMY stock rose after the company announced a strategic AI deal with Anthropic to deploy Claude across its workforce.

BMY : 54.46 (-0.89%)
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline

Late-breaking Phase 3 SUCCESSOR-2 study results highlight potential of mezigdomide, a novel CELMoD from the Company’s targeted protein degradation platform, in relapsed or refractory multiple myeloma...

BMY : 54.46 (-0.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers...

See More

Key Turning Points

3rd Resistance Point 56.68
2nd Resistance Point 56.13
1st Resistance Point 55.30
Last Price 54.46
1st Support Level 53.91
2nd Support Level 53.36
3rd Support Level 52.53

See More

52-Week High 62.89
Fibonacci 61.8% 55.11
Last Price 54.46
Fibonacci 50% 52.70
Fibonacci 38.2% 50.30
52-Week Low 42.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.